Compare Invesco NASDAQ 100 ETF (QQQM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco NASDAQ 100 ETF trades at $309.34 (market cap $113.40B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 11.2× State Street SPDR S&P Biotech ETF's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 54 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| QQQM | XBI | |
|---|---|---|
Market Cap | $113.40B | $10.11B |
Volume | 2,866,236 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $312.76 | $169.55 |
52-Week Low | $229.87 | $104.99 |
Typical Hold Time | 54 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM (Invesco NASDAQ 100 ETF) trades at $309.27, down 0.88% on the day, with a bullish technical signal from moving averages. The ETF tracks the NASDAQ-100 index with a low 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026. Technical indicators show support at $305 and resistance at $311, with neutral oscillator readings suggesting balanced momentum.
The outlook remains positive given the NASDAQ-100's growth exposure and cost efficiency versus QQQ. Risks include market concentration in technology stocks and potential volatility from macroeconomic factors. Institutional accumulation and favorable expense structure support long-term positioning, though investors should monitor index composition changes and broader market trends.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
